GlaxoSmithKline Pharmaceuticals has entered the oncology segment in India, introducing Jemperli and Zejula for gynaecological cancers. These therapies address unmet needs in endometrial and ovarian cancer treatment, with incidence projected to rise significantly by 2045. Jemperli offers targeted immunotherapy for advanced endometrial cancer, while Zejula provides first-line maintenance therapy for advanced ovarian cancer.